Ionis Pharmaceuticals (IONS) Misses Q2 EPS by 20c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ionis Pharmaceuticals (IONS) PT Lowered to $47 at Stifel
August 9, 2018 6:24 AM EDTStifel lowered its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $47.00 (from $48.00) while maintaining a Hold rating.
... MoreStifel Transfers Coverage of Ionis Pharmaceuticals (IONS), Maintains Hold
August 6, 2018 4:19 PM EDTStifel assumes coverage on Ionis Pharmaceuticals (NASDAQ: IONS) with a Hold rating and a price target of $48.00.
Analyst Paul Matteis assumes coverage at Hold and lowers the PT to $48.00 (from $55.00)
For an analyst ratings summary and ratings history on Ionis Pharmaceuticals... More
